Member Info for Bobbler

How dare you be enthusiastic! Such blatant ramping, you should be ashamed of yourself.

That’s put me off a boiled egg for breakfast.

Surfie, like many shares it experienced an unrealistic and inappropriate rise 2 years ago due to covid hype, any share which had the slightest link to c19 followed suit. Thats not the boards fault or a reflection on the company. I suggest you like at others, Novacyt Would be a good example, peaked at circa £12, currently less than 40p.

Sareum has progressed significantly in the past 2 years, to suggest £5 is pie in the sky shows you have a very limited knowledge of the sector you bought into and the potential. Yes, of course there is significant risk but you made a decision to purchase these shares. From reading your posts I get the impression you didn’t and still don’t bother with research, hence the bitter rambling. Maybe best to cut your losses now.

Surfie, if it drops almost daily then how come it’s up 50% over the last 6 months?

Do you have a red nose and big shoes on… is there a flower that squirts water on your chest ? ………..

Ref Thoth, very sad news. I get the impression he lived his life to the full and that is something so many fail to do. As the saying goes….. “life isn’t a dress rehearsal”.

RIP T2

Steve I was being sarcastic, personally (and this is due to being here for over a decade and with a low average) anything north of £6 would be more than another for me. But everyone’s circumstances are different.

Sneckieboy was trying to sow his seeds of doubt. If anyone is worried they can always sell.

Sneckieboy, for once I’m in agreement and share the same fear. There is a danger a buyout could happen around the £8-£12 mark. Let’s hope we don’t sell to low, fingers crossed.

Ref the following comment, just as a matter of balance….

'Will we get there? History says its unlikely.'

Actually, historic data suggests the likelihood improves each year.

Between 2010 and 2019, the number of new drugs approved for sale increased by 60 percent compared with the previous decade, with a peak of 59 new drugs approved in 2018.

It’s AIM, anything can happen, and often does!

We’re making real progress now, patience is required now more than ever. Let the BoD do their thing and hopefully we will see transformational progress, which in turn will be reflected in the SP.

You also Basil, and the same to all on here. It’s a great day, and it’s nice to just have positive posters. It’s still a huge gamble but it sure keeps you on your toes.

Celtic, spot on again :-)

just saying :-)

Just for the record, the 3,500 sell at 8.01 was my purchase.

HBD- hats off, great find.
Be interesting to see where the SP settles once the trial commences, any thoughts welcomed.

Thursday RNS maybe?

Apologies if this has been posted before:

https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00053-1/fulltext

Mendelian randomization and clinical trial evidence supports TYK2 inhibition as a therapeutic target for autoimmune diseases
Findings

Findings

PheWAS-MR found that genetically-proxied TYK2 inhibition was associated with lower risk of a wide range of autoimmune diseases. The associations with hypothyroidism and psoriasis were confirmed in MR analysis of tissue-specific TYK2 gene expression and the associations with systemic lupus erythematosus, psoriasis, and rheumatoid arthritis were observed in colocalization analysis.

Interesting article

Inter article….

“ Tackling inflammation in the body is also being seen as a way of preventing cancer.”

Diamonds

Guess I must be, because I purchased this share at a fraction of what you paid and made a nice lump and still have a significant holding. Wish I could be just like you……….
Clown